SUWANEE, GA, Feb. 02, 2018 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit at EWMA (European Wound Management Association) in Krakow, Poland on May 9 – 11, 2018. This will be a great opportunity to re-invigorate our flagship wound care device, the dermaPACE® System, after receiving US FDA clearance for the treatment of Diabetic Foot Ulcers (DFUs) in December 2017. The dermaPACE system is currently CE Marked within Europe for the treatment of various acute and chronic conditions of the skin.
“We are excited to be presenting at EWMA in Krakow, Poland, our first time as an exhibitor. Since FDA clearance, the support coming from the wound care community has been overwhelmingly positive, both domestically and internationally,” stated Kevin A. Richardson, CEO and Chairman of the Board. Mr. Richardson continued, “This will be the start of our reemergence in the wound care space.” The Company is using this occasion to showcase their lead wound care product, the dermaPACE System. This Extracorporeal Shockwave Technology (ESWT) device based upon electrohydraulic principles has been proven, in two US-based randomized-controlled clinical trials enrolling 336 subjects, to be safe and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with dermaPACE reduce in area at superior rates compared to control subjects. The dermaPACE System exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment. The use of the dermaPACE System allows the clinician to more easily, and more cost-effectively, manage wounds. More importantly, the patient’s quality of life improves significantly. While new to the U.S. market, the dermaPACE System already enjoys a strong support base in Italy, Spain, and the BeNeLex countries. Additional distribution bases include: Germany, Austria, Switzerland, Romania and Great Britain.
If you are interested in scheduling a meeting with the team, please contact Peter Stegagno via e-mail at email@example.com; otherwise, please stop by our booth at the conference in May.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact: Millennium Park Capital LLC Christopher Wynne 312-724-7845 firstname.lastname@example.org SANUWAVE Health, Inc. Peter Stegagno Vice President Operation, Regulatory, and Clinical 678-578-0111 (Office) 678-670-9478 (Mobile) email@example.com